SHR-1703
Unknown / undisclosed
Evidence outlook · registrational
Eosinophilic Granulomatosis with Polyangiitis: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2028-12.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other IL-5 drugs
3 other tracked programmes target this mechanism, 2 of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| SHR-1703: this drug | Phase 2/3 | Undisclosed | IL-5 | not yet graded | No reviewed efficacy summary | |
| Depemokimab | Approved(overall) | Monoclonal antibody | IL-5 | Reliable signal | NCT05274750: Change From Baseline in Total Endoscopic Nasal Polyps (NP) Score at Week 52 (Centrally Read) (Baseline (Day 1) and at Week 52): Depemokimab -0.6 Scores on a Scale (Standard Error 0.14) vs Placebo 0.2 Scores on a Scale (Standard Error 0.15) NCT05281523: Change From Baseline in Total Endoscopic Nasal Polyps (NP) Score at Week 52 (Centrally Read) (Baseline (Day 1) and at Week 52): Depemokimab -0.5 Scores on scale (Standard Error 0.14) vs Placebo 0.1 Scores on scale (Standard Error 0.15) | |
| Mepolizumab (Nucala) | Approved(overall) | Monoclonal antibody | IL-5, Interleukin-5 (IL-5), ligand-neutralizing | Reliable signal | NCT04133909: Annualized Rate of Moderate or Severe Exacerbations (Up to Week 104): Mepolizumab 100 mg 0.8 Exacerbations per year (95% CI 0.7 to 0.91) | Placebo 1.01 Exacerbations per year (95% CI 0.89 to 1.15) NCT01691508: Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control (Baseline; Weeks 20 to 24): Mepolizumab 100 mg SC — 90 to 100%: 16/69; 75 to <90%: 12/69; 50 to <75%: 9/69; >0 to <50%: 7/69; No decrease /lack of asthma control/early WD: 25/69 vs Placebo — 90 to 100%: 7/66; 75 to <90%: 5/66; 50 to <75%: 10/66; >0 to <50%: 7/66; No decrease /lack of asthma control/early WD: 37/66 | |
| BAT2606 | Phase 1(overall) | Monoclonal antibody | IL-5 | Partial signal | NCT05576454: In 207 subjects enrolled and randomized, the 90% confidence intervals of the geometric mean ratios of maximum concentration and area under the curve from time 0 to infinity were within 80.00%-125.00%. |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow SHR-1703 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.